Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Valeant Pharmaceuticals International, Inc. Snapshot | 7 | 1 |
| Valeant Pharmaceuticals International, Inc. Overview | 7 | 1 |
| Key Information | 7 | 1 |
| Key Facts | 7 | 1 |
| Valeant Pharmaceuticals International, Inc. Research and Development Overview | 8 | 3 |
| Key Therapeutic Areas | 8 | 3 |
| Valeant Pharmaceuticals International, Inc. Pipeline Review | 11 | 7 |
| Pipeline Products by Stage of Development | 11 | 1 |
| Pipeline Products Monotherapy | 12 | 1 |
| Pipeline Products Combination Treatment Modalities | 13 | 1 |
| Pipeline Products Partnered Products | 14 | 1 |
| Partnered Products/Combination Treatment Modalities | 15 | 1 |
| Pipeline Products Out-Licensed Products | 16 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 17 | 1 |
| Valeant Pharmaceuticals International, Inc. Pipeline Products Glance | 18 | 6 |
| Valeant Pharmaceuticals International, Inc. Late Stage Pipeline Products | 18 | 1 |
| Pre-Registration Products/Combination Treatment Modalities | 18 | 1 |
| Phase III Products/Combination Treatment Modalities | 19 | 1 |
| Valeant Pharmaceuticals International, Inc. Clinical Stage Pipeline Products | 20 | 1 |
| Phase II Products/Combination Treatment Modalities | 20 | 1 |
| Phase I Products/Combination Treatment Modalities | 21 | 1 |
| Valeant Pharmaceuticals International, Inc. Early Stage Pipeline Products | 22 | 1 |
| Preclinical Products/Combination Treatment Modalities | 22 | 1 |
| Valeant Pharmaceuticals International, Inc. - Unknown Stage Pipeline Products | 23 | 1 |
| Unknown Products/Combination Treatment Modalities | 23 | 1 |
| Valeant Pharmaceuticals International, Inc. Drug Profiles | 24 | 34 |
| brodalumab | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 2 |
| (halobetasol propionate + tazarotene) | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| budesonide | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 4 |
| IDP-122 | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| loteprednol etabonate next generation | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| rifaximin DR | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| BLO-020 | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| ezogabine | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 3 |
| IDP-120 | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| IDP-121 | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| IDP-125 | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| IDP-126 | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| IDP-127 | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| IDP-128 | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| IDP-129 | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 1 |
| IDP-130 | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 1 |
| IDP-131 | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 1 |
| lapuleucel-T | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 2 |
| ribavirin | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| R&D Progress | 49 | 1 |
| SAL-021 | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 1 |
| SPT-201 | 52 | 1 |
| Product Description | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| R&D Progress | 52 | 1 |
| metyrosine | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 1 |
| BLO-021 | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 1 |
| IDP-123 | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| IDP-124 | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 1 |
| VALBRO-03 | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 1 |
| Valeant Pharmaceuticals International, Inc. Pipeline Analysis | 58 | 6 |
| Valeant Pharmaceuticals International, Inc. Pipeline Products by Target | 58 | 2 |
| Valeant Pharmaceuticals International, Inc. Pipeline Products by Route of Administration | 60 | 1 |
| Valeant Pharmaceuticals International, Inc. Pipeline Products by Molecule Type | 61 | 1 |
| Valeant Pharmaceuticals International, Inc. Pipeline Products by Mechanism of Action | 62 | 2 |
| Valeant Pharmaceuticals International, Inc. Recent Pipeline Updates | 64 | 9 |
| Valeant Pharmaceuticals International, Inc. Dormant Projects | 73 | 2 |
| Valeant Pharmaceuticals International, Inc. Discontinued Pipeline Products | 75 | 3 |
| Discontinued Pipeline Product Profiles | 75 | 1 |
| ATON-004 | 75 | 1 |
| (bupropion hydrochloride + selective serotonin reuptake inhibitor) | 75 | 1 |
| brodalumab | 75 | 1 |
| CVTE-002 | 76 | 1 |
| ezogabine | 76 | 1 |
| IDP-107 | 76 | 1 |
| IDP-109 | 76 | 1 |
| IDP-115 | 76 | 1 |
| MC-5 | 76 | 1 |
| methylnaltrexone bromide | 76 | 1 |
| pegaptanib sodium | 76 | 1 |
| rifaximin | 76 | 1 |
| RUS-350 | 77 | 1 |
| taribavirin hydrochloride | 77 | 1 |
| tiazofurin | 77 | 1 |
| UK-279276 | 77 | 1 |
| Valeant Pharmaceuticals International, Inc. Company Statement | 78 | 3 |
| Valeant Pharmaceuticals International, Inc. Locations And Subsidiaries | 81 | 8 |
| Head Office | 81 | 1 |
| Other Locations &Subsidiaries | 81 | 8 |
| Appendix | 89 | 2 |
| Methodology | 89 | 1 |
| Coverage | 89 | 1 |
| Secondary Research | 89 | 1 |
| Primary Research | 89 | 1 |
| Expert Panel Validation | 89 | 1 |
| Contact Us | 89 | 1 |
| Disclaimer | 90 | 1 |